Co-Diagnostics, Inc. to Exhibit at BioUtah's 2025 Life Sciences Day on the Hill
Co-Diagnostics (CODX) announced its participation at BioUtah's Life Sciences Day on the Hill at the Utah State Capitol Rotunda on January 30, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Co-Diagnostics (CODX) announced its participation at BioUtah's Life Sciences Day on the Hill at the Utah State Capitol Rotunda on January 30, 2025. The event, presented by the Utah Life Sciences Innovation Caucus, the Utah Governor's Office of Economic Opportunity, and BioUtah, features over 25 Utah life sciences companies.
At the event, Co-Dx will showcase its upcoming Co-Dx PCR testing platform for at-home and point-of-care detection of infectious diseases, including COVID-19, influenza, RSV, HPV, and tuberculosis. The platform features cloud-based analysis capabilities for tracking disease outbreaks and is operated through a smartphone interface.
The company notes that the Co-Dx PCR platform, including the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and associated tests and software, is currently under FDA review and not yet available for sale.
Details
News Market Reaction – CODX
The recorded move for CODX in the trading session of this news was -0.21%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Life Sciences Day on the Hill is presented by the Utah Life Sciences Innovation Caucus, the
The event follows the Company's participation with the
This year's event takes place today, January 30, from 11:00 AM to 2:00 PM MST, and is expected to feature exhibits from over 25 Utah life sciences companies. Co-Dx's booth will showcase the Company's upcoming at-home and point-of care Co-Dx PCR testing platform* for detection of infectious diseases, including COVID-19, influenza, RSV, HPV and tuberculosis. The platform also incorporates cloud-based analysis to help build situational awareness and provide support to track infectious disease outbreaks at the community and regional level, all operated via an intuitive smartphone interface.
*The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-exhibit-at-bioutahs-2025-life-sciences-day-on-the-hill-302364228.html
SOURCE Co-Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.